HP007 monotherapy for relapsed or advanced solid tumors

Inclusion Criteria:

* Male/female, 18-75 years inclusive.
* Histologically-confirmed unresectable advanced tumors (breast cancer, HNSCC, cutaneous melanoma, prostate cancer, HCC, etc.);
* no effective standard therapy or disease relapse/metastasis post-standard-of-care.
* ECOG PS 0-1;
* expected survival ≥3 months.
* At least 1 measurable lesion by RECIST 1.1. Lesion in prior radiation field must have confirmed progression ≥4 weeks post-radiation. Prostate cancer subjects must meet PCWG3 progression criteria.
* At least one lesion suitable for repeated intratumoral injection.
* Adequate hematopoietic and organ function:
* Males and females of child-bearing potential agree effective contraception from ICF signature to 3 months after last dose.
* Voluntarily sign ICF and comply with study procedures.

Exclusion Criteria:

1. Past/current medical conditions

   * CNS or leptomeningeal metastasis.
   * Residual toxicity from prior anti-tumor therapy \>Grade 1 (CTCAE 6.0), except alopecia and Grade 2 peripheral neuropathy without safety risk.
   * Poorly controlled pleural / ascitic / pericardial effusion requiring local intervention or repeated drainage.
   * Active autoimmune disease or high-risk history of recurrence; organ transplant with immunosuppression.
   * Interstitial lung disease / non-infectious pneumonitis; pulmonary embolism within prior 12 weeks.
   * Severe cardio-cerebrovascular events within 6 months; QTcF ≥470 msec; LVEF ≤50%; NYHA ≥III heart failure; history of long-QT syndrome or ongoing QTc-prolonging drugs.
   * Uncontrolled hypertension (SBP\>160 mmHg and/or DBP\>100 mmHg) or other uncontrolled systemic diseases.
   * High bleeding risk / coagulation disorders: inherited/acquired bleeding-thrombotic predisposition; major bleeding within 3 months; thrombolytics within 10 days; ongoing anticoagulant/antiplatelet therapy (except heparin for CVC patency).
   * Immunodeficiency; history of solid-organ or hematopoietic stem-cell transplantation.
   * Active TB within past 5 years.
   * Severe infection / trauma / GI perforation / fistula / tumor vascular invasion / bowel obstruction within 4 weeks; active infection or antibiotic use within prior 2 weeks (prophylaxis allowed); unexplained fever \>38.5 ℃ (tumor-related fever may be allowed per Investigator judgment).
   * Other active malignancy within 3 years, except: cervical carcinoma in-situ, local basal-cell carcinoma, or malignancies cured ≥5 years without recurrence.
2. Prior medications \& treatments

   * Local radiotherapy completed \<1 week before first dose; \>30% bone-marrow / extensive-field radiotherapy completed \<4 weeks before first dose.
   * Anti-tumor therapy within 4 weeks or less than 5 half-lives (whichever shorter).
   * Systemic corticosteroids (\>10 mg prednisone equivalent/day) or other immunosuppressants within 14 days.
   * Prior immunotherapy with irAEs ≥Grade 3.
   * Prior systemic TLR-agonist treatment (topical TLR agonists e.g. imiquimod permitted).
   * Vaccination within 1 month prior to enrolment.
3. Allergy, general status \& others

   * Severe hypersensitivity (CTCAE 6.0 ≥Grade 3) to any investigational product component.
   * Active HBV / HCV, positive syphilis or HIV serology.
   * Participated in another interventional clinical trial within 4 weeks.
   * Major surgery within 4 weeks before screening or planned major surgery during study.
   * Alcohol / illicit-drug / substance abuse within 12 months.
   * Documented neurological/psychiatric disorders leading to poor compliance.
   * Pregnant or lactating females.
   * Subjects judged unsuitable by the Investigator for any other reason.